Octapharma and Pharmimex to build plant for human factor VIII products in Russia

Pharmimex, one of Russia’s leading drugmakers, and the Swedish unit of Swiss biotech firm Octapharma, have announced plans to invest up to 6 billion roubles ($102 million) in building of a new manufacturing plant for human cell-line derived recombinant factor VIII products in the Russian region of Ryazan.

According to Alexander Apazov, president of Pharmimex, that will be full-cycle production of drugs such as von Willebrand factor, human factor VIII, stabilized with von Willebrand factor, human factor IX, concentrate immunoglobulin 5%, immunoglobulin 10% and some others.

The beginning of the construction of the plant is scheduled for 2017. The plant will reach its full design capacity in 2022.